Who is sponsoring NCT02629809?

NCT02629809 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02629809?

Interventions in NCT02629809: Cyclophosphamide, Fludarabine Phosphate, Ibrutinib, Obinutuzumab.

What condition does NCT02629809 study?

NCT02629809 studies Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

Is NCT02629809 still recruiting?

NCT02629809 is currently active, enrolled. Last updated 6 March 2026.

Last reviewed 2026-03-06 · How we verify

NCT02629809

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Active, enrolled Phase 2 Last updated 6 March 2026

What this trial tests

Phase 2 trial testing Cyclophosphamide in Chronic Lymphocytic Leukemia in 81 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 March 2016

Primary endpoint
31 March 2028

31 March 2028

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	81
Start date	18 March 2016
Primary completion	31 March 2028
Estimated completion	31 March 2028
Sites	1 location across United States

Drugs / interventions tested

Cyclophosphamide (cyclophosphamide) — full drug profile →
Fludarabine Phosphate (FLUDARABINE PHOSPHATE) — full drug profile →
Ibrutinib (ibrutinib) — full drug profile →
Obinutuzumab — full drug profile →

Conditions studied

Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
Small Lymphocytic Lymphoma — all drugs for Small Lymphocytic Lymphoma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab together may work better in treating chronic lymphocytic leukemia.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

From Biology to Therapy: The CLL Success Story.
Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. · · 2019 · cited 48× · PMID 31723816 · DOI 10.1097/hs9.0000000000000175
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N, Thompson P, Burger J, Ferrajoli A, et al · · 2021 · cited 34× · PMID 34007049 · DOI 10.1038/s41375-021-01280-8
The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.
Skarbnik AP, Faderl S. · · 2017 · cited 17× · PMID 28246553 · DOI 10.1177/2040620716681749
Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
Wierda WG, Kipps TJ, Al-Sawaf O, Chyla B, et al · · 2022 · cited 3× · PMID 35983732 · DOI 10.1080/10428194.2022.2098291
Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
Abou Zahr A, Bose P, Keating MJ. · · 2017 · cited 1× · PMID 28446054 · DOI 10.1080/14656566.2017.1324420
First-line therapy for young patients with CLL.
Jain N, O'Brien S. · · 2016 · cited 1× · PMID 27913473 · DOI 10.1182/asheducation-2016.1.146
EHA2024 Hybrid Congress
· 2024
Abstract Book for the 27th Congress of the European Hematology Association
· 2022

Verify or expand the search:

Other trials of Cyclophosphamide

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07509008 — Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Manageme · Phase 1, PHASE2 · not yet recruiting
NCT07444632 — Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/ · Phase 1 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Chronic Lymphocytic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07288515 — Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus · recruiting
NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02629809 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 6 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02629809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing